Di Cesare, Antonella, et al. “Therapeutic Modulation Of Peripheral Blood Cells And Inflammatory Indices During 52 Weeks Of Risankizumab In Responder Patients With Moderate-to-Severe Psoriasis: Results From A Multicenter Prospective Study”. Dermatology Practical & Conceptual, vol. 15, no. 4, Oct. 2025, p. 5733, https://doi.org/10.5826/dpc.1504a5733.